// App-Quantinova.ai

e21552 : Ipilimumab with anti PD-1 (nivovlumab or pembrolizumab) after progression on first line anti-PD-1 therapy for advanced melanoma.

Researchers

Presenter

  • Inderjit Mehmi

Principal Investigators

  • Jordan Hill

Medical Centers

  • WVU Cancer Institute of WVU Medicine, Morgantown, WV

  • WVU Cancer Institute of WVU Medicine, Morgantown, WV

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Pembrolizumab

  • Ipilimumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved